Houin G, Lapeyre C, Rochas M A, Tufenkji A E, Campistron G, Coulais Y, Akbaraly J P, Grislain L, Beck H
Unité de Pharmacocinétique Clinique, Centre Hospitalier Régional Purpan, France.
Arzneimittelforschung. 1993 Jan;43(1):50-3.
The pharmacokinetics of fentiazac (F, CAS 18046-21-4) and hydroxyfentiazac (OH-F) were estimated in 12 elderly (> 76 years). After an oral single dose of 200 mg F, the plasma and urine profiles were determined using high-performance liquid chromatography with a fluorescence detection. When compared to results obtained in young adults, the maximum plasma concentrations (5.4 +/- 1.9 mg/l) and-the time to reach them were identical. The terminal half-life (7.0 +/- 9.1 h) was longer, due to a slight increase of the apparent volume of distribution and a decrease of the elimination clearance. The findings suggest that the dosage regimen of this drug should be decreased in the elderly. Moreover, the variability of the pharmacokinetics being larger, individual adaptation of the daily dose should be performed.
在12名老年患者（年龄>76岁）中评估了芬替扎酸（F，化学物质登记号18046 - 21 - 4）和羟基芬替扎酸（OH - F）的药代动力学。口服单剂量200mg F后，采用高效液相色谱荧光检测法测定血浆和尿液浓度曲线。与年轻成年人的结果相比，血浆最大浓度（5.4±1.9mg/L）及其达峰时间相同。由于表观分布容积略有增加和消除清除率降低，终末半衰期（7.0±9.1小时）更长。这些研究结果表明，老年人使用该药物时剂量方案应减少。此外，药代动力学变异性更大，应根据个体情况调整每日剂量。
